Compare with COLINZ LABOR - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN PHARMACEUTICALS vs COLINZ LABOR - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN PHARMACEUTICALS COLINZ LABOR SUVEN PHARMACEUTICALS/
COLINZ LABOR
 
P/E (TTM) x 44.0 38.6 114.1% View Chart
P/BV x 11.5 1.3 861.0% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 SUVEN PHARMACEUTICALS   COLINZ LABOR
EQUITY SHARE DATA
    SUVEN PHARMACEUTICALS
Mar-21
COLINZ LABOR
Mar-20
SUVEN PHARMACEUTICALS/
COLINZ LABOR
5-Yr Chart
Click to enlarge
High Rs52510 5,174.9%   
Low Rs1036 1,715.0%   
Sales per share (Unadj.) Rs39.721.1 188.0%  
Earnings per share (Unadj.) Rs12.10.4 3,301.1%  
Cash flow per share (Unadj.) Rs13.40.9 1,455.8%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs46.419.3 240.1%  
Shares outstanding (eoy) m254.573.54 7,191.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x7.90.4 2,067.0%   
Avg P/E ratio x25.921.9 118.1%  
P/CF ratio (eoy) x23.58.8 267.1%  
Price / Book Value ratio x6.80.4 1,617.8%  
Dividend payout %16.50-   
Avg Mkt Cap Rs m79,95329 279,383.3%   
No. of employees `000NANA-   
Total wages/salary Rs m76233 2,343.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,09775 13,517.0%  
Other income Rs m1421 10,545.9%   
Total revenues Rs m10,24076 13,464.2%   
Gross profit Rs m4,4303 146,205.3%  
Depreciation Rs m3162 16,223.6%   
Interest Rs m1171 17,410.4%   
Profit before tax Rs m4,1392 235,192.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0530 228,982.6%   
Profit after tax Rs m3,0861 237,389.2%  
Gross profit margin %43.94.1 1,082.6%  
Effective tax rate %25.425.9 98.2%   
Net profit margin %30.61.7 1,750.3%  
BALANCE SHEET DATA
Current assets Rs m6,66558 11,405.6%   
Current liabilities Rs m3,21516 19,994.2%   
Net working cap to sales %34.256.7 60.3%  
Current ratio x2.13.6 57.0%  
Inventory Days Days20044 450.4%  
Debtors Days Days37073 507.9%  
Net fixed assets Rs m9,09730 30,659.9%   
Share capital Rs m25535 718.3%   
"Free" reserves Rs m11,55433 35,074.4%   
Net worth Rs m11,80868 17,268.3%   
Long term debt Rs m3560-   
Total assets Rs m15,76288 17,889.3%  
Interest coverage x36.53.6 1,006.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.8 75.6%   
Return on assets %20.32.2 907.8%  
Return on equity %26.11.9 1,370.1%  
Return on capital %35.03.6 985.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,9020-   
Fx outflow Rs m1,3690-   
Net fx Rs m8,5330-   
CASH FLOW
From Operations Rs m3,8346 65,996.2%  
From Investments Rs m-3,114NA 819,468.4%  
From Financial Activity Rs m-7661 -123,472.6%  
Net Cashflow Rs m-456 -746.0%  

Share Holding

Indian Promoters % 60.0 36.4 164.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 13.8 0.1 19,771.4%  
FIIs % 8.0 0.1 11,471.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 40.0 63.6 62.9%  
Shareholders   96,532 2,421 3,987.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN PHARMACEUTICALS With:   UNJHA FORMUL  SOLARA ACTIVE PHARMA SCIENCES  PIRAMAL ENTERPRISES  ASTRAZENECA PHARMA  SANJIVANI PA  



Today's Market

Sensex Ends 456 Points Lower; Midcap and Smallcap Stocks Witness Heavy Selling(Closing)

After opening the day on a flat note, Indian share markets witnessed heavy selling in the afternoon session and ended lower.

Related Views on News

SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of SUVEN PHARMACEUTICALS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUVEN PHARMACEUTICALS. Also includes updates on the valuation of SUVEN PHARMACEUTICALS.

More Views on News

Most Popular

Is it Time to Switch from Tata Power to NTPC?(Profit Hunter)

Oct 11, 2021

Given the huge run up in Tata Power, does it make sense to switch to NTPC?

This Proxy EV Stock Just got a Power Crisis Boost(Profit Hunter)

Oct 8, 2021

After months of research, I've come across few stocks that excite me far more than the mainstream electric vehicle companies.

Rs 1 Lakh Invested in These Cryptos at the Start of 2021 Became Rs...(Views On News)

Oct 8, 2021

These cryptos would have multiplied investors' wealth by as much as 10,000% in just nine months.

5 Exciting 'Unlisted' Companies and How to Play Them(Views On News)

Oct 7, 2021

Here's how you can invest in some of the most exciting start-ups of the decade.

Modi's Big Move Could Boost these 5 Defence Stocks(Views On News)

Oct 11, 2021

To corporatise the defence sector, the Ministry of Defence (MoD) has dissolved the 250-year-old Ordnance Factory Board (OFB).

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN PHARMACEUTICALS SHARE PRICE


Oct 20, 2021 (Close)

TRACK SUVEN PHARMACEUTICALS

  • Track your investment in SUVEN PHARMACEUTICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS 8-QTR ANALYSIS

COMPARE SUVEN PHARMACEUTICALS WITH

MARKET STATS